Retrovir and Pregnancy

While women with HIV commonly use Retrovir during pregnancy, complications remain a potential risk with use of the drug. In animal studies, the medication increased the risk of miscarriages when it was given to pregnant rats. In human studies on Retrovir and pregnancy, however, the medicine did not cause problems and was shown to reduce the risk of HIV infection in newborns by 86.7 percent.

Retrovir and Pregnancy: An Overview

Retrovir® (zidovudine) is a prescription HIV medication that is commonly used in pregnant women. While the full risks of using Retrovir during pregnancy are not currently known, the benefits (for both the mother and the baby) usually outweigh the risks.
 

Retrovir and Pregnancy Category C

The U.S. Food and Drug Administration (FDA) uses a category system to classify the possible risks to a fetus when a specific medicine is taken during pregnancy. Pregnancy Category C is given to medicines that have not been studied in pregnant humans but that do appear to cause harm to the fetus in animal studies. Also, medicines that have not been studied in any pregnant women or animals are automatically given a pregnancy Category C rating.
 
In one study, when Retrovir was given to pregnant rats, it increased the risk of miscarriages but did not seem to increase the risk of birth defects. However, another study suggested that very high doses may cause birth defects in rats. In general, animal studies show that Retrovir is probably safe for use during pregnancy, although there is some evidence that it may affect fertility and very early fetal development.
 
Retrovir has also been studied in pregnant women. In fact, it is approved for use during pregnancy to help prevent the transmission of the HIV virus to the baby. In one study, Retrovir reduced the risk of HIV infection in the newborns by up to 86.7 percent. Overall, these studies showed that the drug did not increase the risk of birth defects or other problems.
 
Starting Retrovir early in pregnancy may decrease the risk of HIV transmission to the baby. However, current guidelines recommend that it is okay for a woman to wait to start Retrovir until she is 10 to 12 weeks pregnant to limit exposure of the fetus to the medicine during early pregnancy (a critical period for organ development).
 
Pregnancy and Pain

Retrovir Therapy -- Drug Information

Referring Pages:
Terms of Use
Advertise with Us
Contact Us
About eMedTV
Privacy Policy
Copyright © 2006-2017 Clinaero, Inc.
eMedTV serves only as an informational resource. This site does not dispense medical advice or advice of any kind. Site users seeking medical advice about their specific situation should consult with their own physician. Click Terms of Use for more information.